Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC.
NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC. Valero, V., Tang, G., Rastogi, P., Geyer, C. E., Colangelo, L. H., Kengla, A., Irvin, W., Socoteanu, M. P., Abraham, J., Esparaz, B. T., Alguire, K. B., Flaherty, L. E., Jatoi, I., Telli, M. L., Makhoul, I., Freeman, T., Yothers, G., Swain, S. M., Mamounas, E. P., Wolmark, N. LIPPINCOTT WILLIAMS & WILKINS. 2025: LBA509View details for DOI 10.1200/JCO.2025.43.17_suppl.LBA509
View details for Web of Science ID 001511770300001